Homocysteine and atherothrombosis
Related Experiment Video
Updated: Oct 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
1Department of Cardiology, Aarhus University Hospital (Skejby), Denmark. Erling.Falk@iekf.au.dk
Insights
Current evidence does not establish homocysteine as a cause of atherothrombotic diseases like ischemic heart disease. Elevated homocysteine may be a marker, not a cause, of these conditions.
Area of Science:
- Cardiovascular Science
- Metabolic Disease Research
- Nutritional Epidemiology
Background:
- Atherosclerosis underlies major cardiovascular diseases, including ischemic heart disease (IHD) and stroke.
- The link between homocysteine and atherothrombotic diseases is debated, with conflicting evidence from various study types.
- Severe hyperhomocysteinemia causes cardiovascular issues, but IHD is rare in these patients, unlike in the general population.
Purpose of the Study:
- To critically evaluate the causal role of homocysteine in the pathogenesis of atherothrombotic diseases.
- To assess whether observed associations between plasma homocysteine and IHD meet criteria for causality.
- To explore alternative explanations for the homocysteine-atherothrombosis relationship.
Main Methods:
- Review of genetic, observational, and experimental studies on homocysteine and atherothrombosis.
- Analysis of criteria for inferring causality from observational data (temporality, consistency, strength, etc.).
- Examination of experimental data in animal models, including comparisons between normal and hypercholesterolemic subjects.
Main Results:
- Evidence for a causal role of homocysteine in atherothrombosis is not clearly established, even in genetically hyperhomocysteinemic individuals.
- Epidemiological associations between plasma homocysteine and IHD do not consistently meet causality criteria.
- Plasma homocysteine levels are influenced by diet and may reflect atherothrombosis or associated behaviors rather than causing it.
- Experimental studies show hyperhomocysteinemia is not inherently atherogenic in normal animals.
Conclusions:
- The homocysteine hypothesis of atherosclerosis lacks definitive proof.
- Plasma homocysteine is unlikely to be a direct cause of atherothrombotic disease in the general population.
- Further research in atherogenic animal models is needed to clarify homocysteine's role under specific conditions.
Abstract:
Atherosclerosis with or without thrombosis superimposed is the most frequent cause of ischemic heart disease (IHD), peripheral arterial disease, and a main cause of stroke. Conflicting results have been reported in genetic, observational, and experimental studies on the relationship between homocysteine and these atherothrombotic diseases. Although cardiovascular complications are common in homocystinuric patients (severe hyperhomocysteinemia), IHD, the most frequent manifestation of atherothrombosis in the general population, appears to be rare. On the basis of findings in individuals with hyperhomocysteinemia of genetic origin, there is in fact no clear evidence for a causal role of homocysteine in the pathogenesis of atherothrombotic disease, and the positive association between plasma homocysteine and IHD observed in many, but not all epidemiologic studies does not prove causality. To infer causality from observational studies, there should be a temporal, consistent, strong, independent, graded (dose-response effect), and duration-dependent relationship between exposure and outcomes, and a biologically plausible mechanism should exist. The relationship between plasma homocysteine levels and IHD does not fulfill these criteria beyond reasonable doubt. In the general population, plasma homocysteine levels are to a great extent determined by dietary habits, and plasma homocysteine could be a marker, or a consequence, of atherothrombosis and/or risk-associated behavior (e.g., a diet low in fruits and vegetables) rather than a cause of atherothrombosis. Experimentally, hyperhomocysteinemia is not in itself atherogenic in normal animals with relatively low plasma cholesterol levels. The homocysteine theory of atherosclerosis should be tested more thoroughly in hypercholesterolemic animals that develop atherosclerosis spontaneously to determine whether elevated plasma homocysteine levels are harmful under atherogenic conditions. A causal role of homocysteine in atherothrombotic disease remains to be established.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Cholesterol: Significance and Regulation
Considering cholesterol and...
